Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2003-09-16
2008-03-25
Woodward, Michael P. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S045000, C514S283000
Reexamination Certificate
active
07348025
ABSTRACT:
Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount sufficient to deliver a pharmacologically effective dose of the camptothecin or its derivative to treat the cancer. Also provided is a nebulized liposomal aerosol comprising the DLPC containing the camptothecin or its derivative and a method of making the liposome-drug comprising the aerosol.
REFERENCES:
patent: 4963367 (1990-10-01), Ecanow
patent: 5049388 (1991-09-01), Knight et al.
patent: 5277914 (1994-01-01), Szoka, Jr.
patent: 5366737 (1994-11-01), Eppstein et al.
patent: 5422344 (1995-06-01), Priel et al.
patent: 5552156 (1996-09-01), Burke
patent: 5736156 (1998-04-01), Burke
patent: 5958378 (1999-09-01), Waldrep et al.
patent: 6090407 (2000-07-01), Knight et al.
patent: 6346233 (2002-02-01), Knight et al.
patent: 2004/0208935 (2004-10-01), Giovanella et al.
patent: 4430593 (1994-08-01), None
patent: 0349127 (1990-01-01), None
patent: WO 9318751 (1993-03-01), None
patent: WO 9426253 (1994-05-01), None
patent: WO 9605821 (1995-08-01), None
patent: WO 9619199 (1995-12-01), None
patent: WO 98/00111 (1998-01-01), None
Burke, “Lipid bilayer partitioning and stability of camptothecin drugs,”Biochemistry, 32:5352-5364, 1993.
Hinz et al., “Pharmacokinetics of the in Vivo and in Vitro Conversion of 9-Nitro-20(S)-camptothecin to 9-Amino-20(S)-camptothecin in Humans, Dogs, and Mice,”Cancer Res., 54:3096-3100, 1994.
Lesueur-Ginot et al., “Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties,”Cancer Res., 59:2939-2943, 1999.
Mi et al., “Reduced albumin binding promotes the stability and activity of topotecan in human blood,”Biochemistry, 34:13722-13728, 1998.
Ozer, “Stability studies of 5-FU liposomes,”Drug Targeting Delivery, 1:151-160, 1992.
Schreier et al., “Pulmonary delivery of liposomes,”J. Controlled Release, 24:209-223, 1993.
Sugarman et al., “Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies,”Cancer Chemother Pharmacol., 37:531-538, 1996.
Verschraegen et al., “A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor,”Anti-Cancer Drugs, 9:36-44, 1998.
Verschraegen et al., “Alternative administration of camptothecin analogues,”Ann NY Acad. Sciences, 922:237-246, 2000.
Waldrep et al., “Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition,”Int. J. Pharaceutics, 97:205-212, 1993.
Waldrep et al., “Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates,”J. Aerosol Med., 7:133-145, 1994.
Weibel, “Geometry and dimensions of airways of conductive and transitory zones,” In Morphometry of the Human Lungs, NY: Academic Press Inc., 110-140, 1963.
Zamboni et al., “Phase I and pharmacokinetic (PK) study of intermittently administered 9-nitro-campothecin (9NC, Rubitecan) in patients with advanced malignancies,”Proc. Am. Soc. Clin. Oncol., A411, 2001.
“Chiron submits new drug application for pulminiq; inhaled form of cyclosporine could be first immunosuppressant indicated for chronic lung-transplant rejection,” www.drugs.com
da/pulminiq—041014.html, Sep. 14, 2006.
Abang et al., “The clinical pharmacology of topoisomerase I inhibitors,”Sem Hematol, 35:13-21, 1998.
Ahmed et al., “Influence of route of administration on [3h]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies,”Cancer Chemother Pharmacol., 39:122-130, 1996.
Anderson, “Delivery systems for immunomodulatory proteins and peptides,”BioDrugs, 7:51-65, 1997.
Burckart et al., “Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients,”Pharmaceutical Research, 20:252-256, 2003.
Chourpa et al., “Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA,”Biochem, 37:7284-7291, 1998.
Fresta et al., “Evaluation and optimization of liposomes as delivery device for methotrexate,”Pharmazie, 47:926-929, 1992.
Garcia-Carbonero et al., “Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins,”Clin. Cancer Res., 8:641-661, 2002.
Giovanella et al., “Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin,”Cancer Res., 51:3052-3055, 1991.
Hallman et al., “Inositol supplementation in premature infants with respiratory distress syndrome,”N. Eng. J. Med., 326:1233-1239, 1992.
Hausheer et al., “Karenitecins: a novel, potent class of oral highly lipophillic topo I inhibitors,”Proc. Annu. Meet. Am. Asoc. Cancer Res., 38:A1526, 1997.
Hertzberg et al., “Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity,”J. Medic. Chem., 32:715-720, 1989.
Hochster et al., “Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen,”J. Clin. Oncol., 12:553-559, 1994.
Iacono et al., “Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans,”Eur. Respir. J., 23:384-390, 2004.
Kim et al., “Pharmacodynamics of insulin in polyethylene glycol-coated liposomes,”Int. J. Pharm., 180:75-81, 1999.
Knight et al., “New approaches in aerosol drug delivery for the treatment of asthma,” in Allergy and Allergic Diseases, Kay (ed), Blackwell Publications, Oxford, England, I:730-741, date unknown.
Gilbert Brian
Knight J. Vernon
Koshkina Nadezhda
Verschraegen Claire F.
Fulbright & Jaworski L.L.P.
Research Development Foundation
Sasan Aradhana
Woodward Michael P.
LandOfFree
Small particle liposome aerosols for delivery of anticancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small particle liposome aerosols for delivery of anticancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small particle liposome aerosols for delivery of anticancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975634